


Status: Currently Official on 16-Feb-2025
 Official Date: Official as of 01-Dec-2024
 Document Type: USP Monographs
 DocId: GUID-1F7E59E6-7BC8-4A59-A8F4-BDF94B5394BF_4_en-US
 DOI: https://doi.org/10.31003/USPNF_M80600_04_01
 DOI Ref: zvyaw

© 2025 USPC
 Do not distribute

Technetium Tc 99m Bicisate Injection



DEFINITION

Technetium Tc 99m Bicisate Injection is a sterile, clear, colorless solution, suitable for intravenous administration, of bicisate dihydrochloride complexed to radioactive technetium (^{99m}Tc). It contains NLT 90.0% and NMT 110.0% of the labeled amount of ^{99m}Tc as a complex with bicisate, expressed in megabecquerels (or in millicuries) per milliliter at the time indicated in the labeling. Other chemical forms of radioactivity are NMT 10% of the total radioactivity.

IDENTIFICATION

• A. RADIONUCLIDIC IDENTITY

(See [Radioactivity \(821\)](#), [Identification of Radionuclides](#).)

Acceptance criteria: Its gamma-ray spectrum is identical to that of a specimen of ^{99m}Tc that exhibits a major photopeak having an energy of 0.140 MeV.

Add the following:

▲ • B. RADIOCHEMICAL IDENTITY

Acceptance criteria: The retardation factors of the spots for Tc 99m bicisate and/or Tc(IV) 99m bicisate in the chromatogram of the *Sample* correspond with the ranges stated in the test for *Radiochemical Impurities*. ▲ (USP 1-Dec-2024)

ASSAY

• RADIOACTIVE CONCENTRATION (STRENGTH)

(See [Radioactivity \(821\)](#), [Assay of Radionuclides](#).)

Analysis: Using a suitable counting assembly, determine the radioactivity, in megabecquerels (or millicuries) per milliliter, of the Injection by use of a calibrated system.

Acceptance criteria: 90.0%–110.0% of the labeled amount of ^{99m}Tc at the time indicated in the labeling

PURITY

• RADIONUCLIDIC PURITY

(See [Radioactivity \(821\)](#).)

Analysis: Using a suitable counting assembly, determine the radioactivity of each radionuclidic impurity, in kilobecquerels per megabecquerel (microcuries per millicurie) of technetium 99m, in the Injection by use of a calibrated system.

Acceptance criteria

For Injection prepared from technetium 99m derived from parent molybdenum 99 formed as a result of neutron bombardment of stable molybdenum: See [Table 1](#).

For Injection prepared from technetium 99m derived from parent molybdenum 99 formed as a result of uranium fission—gamma- and beta-emitting impurities: See [Table 2](#).

Table 1

| Radionuclidic Impurity | Most Prominent Photopeaks | Half-Life | Acceptance Criteria, NMT ^a |
|--|---|-----------|---------------------------------------|
| Molybdenum 99 | 0.181 MeV gamma 0.740 MeV gamma 0.780 MeV gamma | 66.0 h | 0.15 kBq/MBq (μCi/mCi) |
| Total of all other gamma-emitting radionuclidic impurities | — | — | 0.5 kBq/MBq (μCi/mCi) ^b |

- ^a Radioactivity of radionuclidic impurity/radioactivity of Tc 99m per administered dose of Injection at the time of administration.
- ^b Does not exceed 92 kBq (2.5 μCi) per administered dose of the Injection at the time of administration.

Table 2

| Radionuclidic Impurity | Most Prominent/Maximum Photopeaks | Half-Life | Acceptance Criteria, NMT ^a |
|---|---|-----------|---------------------------------------|
| Molybdenum 99 | 0.181 MeV gamma 0.740 MeV gamma 0.780 MeV gamma | 66.0 h | 0.15 kBq/MBq (μCi/mCi) |
| Iodine 131 | 0.364 MeV | 8.08 d | 0.05 kBq/MBq (μCi/mCi) |
| Ruthenium 103 | 0.497 MeV | 39.5 d | 0.05 kBq/MBq (μCi/mCi) |
| Strontium 89 ^b | 1.463 MeV beta | 52.7 d | 0.0006 kBq/MBq (μCi/mCi) |
| Strontium 90 ^b | 0.546 MeV beta | 27.7 y | 0.00006 kBq/MBq (μCi/mCi) |
| Gross alpha impurity | — | — | 0.001 Bq/MBq (nCi/mCi) |
| All other beta- and gamma-emitting radionuclidic impurities | — | — | 0.01% |

- ^a Radioactivity of radionuclidic impurity/radioactivity of Tc 99m present at the time of administration.
- ^b Use a counting system appropriate for the detection of particulate radiations.

Change to read:

• RADIOCHEMICAL PURITY

Sample solution: Prepare four vials of Injection and perform the test on each vial.

Chromatographic system

(See [Chromatography \(621\)](#), [General Procedures](#), [Thin-Layer Chromatography](#).)

Mode: TLC

Adsorbent: 2.5-cm × 7.5-cm chromatographic silica gel sheet

Application volume: About 5 μL

Developing solvent system: [Ethyl acetate](#)

Analysis

Sample: ▲The *Sample solution* used to perform this test is also used to perform the test for *Radiochemical Impurities*. Perform the tests in parallel with a minimal delay in spotting of the chromatographic media following the 30-min Injection incubation period.▲ (USP 1-Dec-2024)
Place the *Sample solution* about 2 cm from the bottom of the *Adsorbent* and allow to dry for 5–10 min. Position the plate in a pre-equilibrated chromatographic chamber containing the *Developing solvent system*, and develop the chromatogram until the solvent front has moved 5 cm from the origin. Remove the plate from the chamber, and allow to dry. Cut the chromatographic sheet 4.5 cm from the

bottom. Separately count the activity on each piece in a dose calibrator or a gamma counter. The activity on the upper portion contains the ^{99m}Tc bicisate complex, and the activity on the lower section contains all radioimpurities. Calculate the percentage of radiochemical purity of the Injection taken:

Result = 100P/(P + C)

- P = count from the top part of the sheet
- C = count from the bottom part of the sheet

Acceptance criteria: NLT 90% of the total radioactivity is found as Tc^{99m} bicisate. Calculate the mean percentage of radiochemical purity of the four test vials.

IMPURITIES

Change to read:

- RADIOCHEMICAL IMPURITIES

▲ (USP 1-Dec-2024)

Chromatographic system

(See [Chromatography \(621\), General Procedures, Thin-Layer Chromatography.](#))

- Mode: TLC
- Adsorbent: 2.5-cm × 7.5-cm reverse-phase thin-layer chromatographic plate (or equivalent)
- Developing solvent system: [Acetone](#) and 0.5 M [ammonium acetate](#) (60:40)
- Application volume: About 2 µL

Analysis

Sample: *Sample solution* used to perform the test for *Radiochemical Purity*. Perform the tests in parallel with a minimal delay in spotting of the chromatographic media following the 30-min Injection incubation period. Apply the *Sample* 1 cm from the bottom of the *Adsorbent*, and allow the spot to air-dry thoroughly. Develop the chromatogram until the solvent front has moved 7 cm from the origin. Remove the plate from the chamber and air-dry. Using a suitable calibrated scanner, determine the compounds present by calculating the retention factors for all peaks present. Compounds and approximate *R_F* values are shown in [Table 3](#).

Table 3

| Compound | Approximate <i>R_F</i> Value |
|--|--|
| ^{99m} Tc bicisate | 0.15–0.44 |
| ^{99m} Tc(IV) bicisate | 0.3–0.4 |
| ^{99m} Tc bicisate and ^{99m} Tc(IV) bicisate | 0.15–0.44 |
| Hydrolyzed reduced Tc | 0.00–0.14 |
| Free pertechnetate and ^{99m} Tc ethylene cisteinate monomer | 0.70–0.84 |
| ^{99m} Tc EDTA | 0.95–1.0 |

Calculate the quantity of ^{99m}Tc(IV) ligand in the Injection by subtracting the ^{99m}Tc bicisate percentage obtained in the test for *Radiochemical Purity* from the combined ^{99m}Tc bicisate and ^{99m}Tc(IV) bicisate area percentage obtained in the test for *Radiochemical Impurities*.

Acceptance criteria: The sum of the impurities is NMT 10%.

SPECIFIC TESTS

Add the following:

- ▲ **APPEARANCE:** Clear, colorless solution, free from visible particulates▲ (USP 1-Dec-2024)

Change to read:

- **BACTERIAL ENDOTOXINS TEST (85):** ▲Meets the requirements. The Injection may be distributed or dispensed prior to completion of the test.▲ (USP 1-Dec-2024)

Add the following:

- ▲• **STERILITY TESTS (71):** Meets the requirements. The Injection may be distributed or dispensed prior to completion of the test.▲ (USP 1-Dec-2024)

Delete the following:

- ▲• **OTHER REQUIREMENTS**▲ (USP 1-Dec-2024)

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in single-dose or multiple-dose containers, at controlled room temperature.
- **LABELING:** Label the Injection to include the following, in addition to the information specified under [Labeling \(7\), Labels and Labeling for Injectable Products](#): the time and date of calibration; the amount of ^{99m}Tc as labeled bicisate expressed as total megabecquerels (or millicuries) per milliliter at the time of calibration; the expiration date and time; the lot number; and the statement: [**CAUTION—Radioactive Material**]. The labeling indicates that, in making dosage calculations, correction is to be made for radioactive decay, and also indicates that the radioactive half-life of ^{99m}Tc is 6.0 h.

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question | Contact | Expert Committee |
|--------------------------------------|---|---------------------------|
| TECHNETIUM TC 99M BICISATE INJECTION | Documentary Standards Support | SM42020 Small Molecules 4 |
| REFERENCE STANDARD SUPPORT | RS Technical Services RSTECH@usp.org | SM42020 Small Molecules 4 |

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 49(1)

Current DocID: GUID-1F7E59E6-7BC8-4A59-A8F4-BDF94B5394BF_4_en-US

DOI: https://doi.org/10.31003/USPNF_M80600_04_01

DOI ref: [zyyaw](#)